ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.

aTyr Pharma, Inc. (the Company) is participating at the American
Thoracic Societys (ATS) 113thInternational Conference
to be held May 19 24, 2017 in Washington D.C. and will be
presenting two poster presentations at such conference.The
posters are titled Resokine Modulates Immune Cell Infiltration
into the Lung and Provides Therapeutic Activity in a
Bleomycin-Induced Lung Fibrosis Model, to be presented on May 23,
2017, and The Resokine Pathway is Implicated in the Pathology of
Interstitial Lung Disease, to be presented on May 24, 2017. These
posters are attached hereto as Exhibit 99.1 and Exhibit 99.2,
respectively.

In conjunction with the ATS poster presentations, the Company
will host an educational webinar on Tuesday, May 23, 2017 at 8:30
a.m. ET featuring Steven D. Nathan, M.D., FCCP, Director of the
Advanced Lung Disease Program and Medical Director of the Lung
Transplant Program at Inova Fairfax Hospital, to provide disease
education on interstitial lung diseases that are characterized by
an immune or fibrotic component. The Company will also provide an
overview of the iMod.Fc program (Stalaris) in development for the
potential treatment of patients with severe, rare pulmonary
diseases characterized by an immune or fibrotic component for
whom there are limited treatment options. A copy of the
presentation materials for such educational webinar is attached
hereto as Exhibit 99.3.The Company does not undertake to update
the presentation materials.

The information under this Item 7.01, including Exhibits 99.1,
99.2 and 99.3 hereto, is being furnished and shall not be deemed
filed for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall such information be
deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.

Item 9.01 Exhibits.

(d) Exhibits.

99.1

Poster presentation titled Resokine Modulates Immune Cell
Infiltration into the Lung and Provides Therapeutic
Activity in a Bleomycin-Induced Lung Fibrosis Model.

99.2

Poster presentation titled The Resokine Pathway is
Implicated in the Pathology of Interstitial Lung Disease.

99.3

Educational Webinar Materials of aTyr Pharma, Inc. dated
May 23, 2017.


About ATYR PHARMA, INC. (NASDAQ:LIFE)

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

ATYR PHARMA, INC. (NASDAQ:LIFE) Recent Trading Information

ATYR PHARMA, INC. (NASDAQ:LIFE) closed its last trading session up +0.15 at 3.55 with 57,442 shares trading hands.

An ad to help with our costs